Related references
Note: Only part of the references are listed.Understanding why patients with immune thrombocytopenia are deeply divided on splenectomy
Karen K. W. Wang et al.
HEALTH EXPECTATIONS (2014)
Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care
David J. Kuter et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia
Donald M. Arnold et al.
BLOOD (2012)
Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia
Vivek L. Patel et al.
BLOOD (2012)
Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis
Sophie Auger et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Evaluation of bleeding-related episodes in patients with immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care
Roberto Stasi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2012)
A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia
James B. Bussel et al.
BLOOD (2011)
Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program
Mehdi Khellaf et al.
BLOOD (2011)
The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia
Cindy Neunert et al.
BLOOD (2011)
Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study
Gregory Cheng et al.
LANCET (2011)
Piecing Together the Humoral and Cellular Mechanisms of Immune Thrombocytopenia
Lisa J. Toltl et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2011)
Current Controversies in the Formation and Treatment of Alloantibodies to Factor VIII in Congenital Hemophilia A
Rebecca Kruse-Jarres
HEMATOLOGY-AMERICAN SOCIETY HEMATOLOGY EDUCATION PROGRAM (2011)
TPO receptor agonist for chronic idiopathic thrombocytopenic purpura
Yan Zeng et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2011)
Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura
Donald M. Arnold et al.
BLOOD (2010)
Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents
Weili Bao et al.
BLOOD (2010)
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia.
David J. Kuter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Toxicities of the Thrombopoietic Growth Factors
Adam Cuker
SEMINARS IN HEMATOLOGY (2010)
Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP
James B. Bussel et al.
BLOOD (2009)
New treatments for idiopathic thrombocytopenic purpura: rethinking old hypotheses
Donald M. Arnold et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Mapping helper T-cell epitopes on platelet membrane glycoprotein IIIa in chronic autoimmune thrombocytopenic purpura
Hosea Sukati et al.
BLOOD (2007)
Systematic review: Efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura
Donald M. Arnold et al.
ANNALS OF INTERNAL MEDICINE (2007)
AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP
James B. Bussel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Share Paper
